Novartis Ag

University of Pennsylvania

Guoliang Xun

Feng He

Qitao Xiao

Yue Ping Li

Lei Liu

Yuan Mi

Zhengtian Yu

Ji Yue Zhang

Miao Dai

Yao-Chang Xu

Xingnian Fu

Lei Jiang

Ce Wang

Fang Liang

Haibing Deng

Qiangang Zheng

Xiaoxia Yan

Counde Oyang

Jinbiao Liu

Haiqiang Zeng

Lei Du-Cuny

Gregory Motz

Konstantinos John Mavrakias

The present invention provides a compound of Formula (I):

Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents

The present invention provides a compound of Formula (I): 

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R, R, R, R, and Rare as defined herein.

Substituted 5-cyanoindole compounds and uses thereof

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R, R, R, R, R, and Rare as defined herein.

Cyano-substituted indoles as LSD1 inhibitors

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Heterocyclic oxime compounds

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I). 

Heterocyclic hydrazone compounds

Growing community of inventors

Taicang, China

Guoliang Xun